Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock had its "outperform" rating reiterated by stock analysts at Royal Bank Of Canada in a research report issued on Tuesday, Benzinga reports. They currently have a $1,600.00 price objective on the stock. Royal Bank Of Canada's target price indicates a potential upside of 12.00% from the company's previous close.
LLY has been the topic of a number of other research reports. UBS Group boosted their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a "buy" rating in a research note on Friday, October 30th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an "overweight" rating in a report on Friday, October 30th. Scotiabank increased their price target on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a "sector outperform" rating in a research report on Friday, October 30th. Finally, HSBC increased their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a "reduce" rating in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,422.00.
Check Out Our Latest Stock Analysis on LLY
Eli Lilly and Company Stock Down 0.2%
Shares of NYSE:LLY opened at $1,428.61 on Tuesday. The stock has a market cap of $1.34 trillion, a price-to-earnings ratio of 45.90, a PEG ratio of 1.71 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,475.25. The business's 50 day moving average is $1,247.93 and its 200 day moving average is $1,112.33.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts' consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period in the prior year, the firm posted $7.02 EPS. Eli Lilly and Company's quarterly revenue was up 38.6% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Insider Buying and Selling
In other news, EVP Anat Hakim sold 5,000 shares of the company's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Eli Lilly and Company
Several hedge funds have recently bought and sold shares of LLY. Aspen Grove Capital LLC lifted its stake in Eli Lilly and Company by 3.5% during the third quarter. Aspen Grove Capital LLC now owns 4,455 shares of the company's stock worth $5,157,000 after purchasing an additional 152 shares during the last quarter. Ausdal Financial Partners Inc. raised its holdings in shares of Eli Lilly and Company by 0.9% during the 3rd quarter. Ausdal Financial Partners Inc. now owns 8,306 shares of the company's stock valued at $9,611,000 after buying an additional 75 shares in the last quarter. Lighthouse Investment Partners LLC raised its holdings in shares of Eli Lilly and Company by 12.0% during the 3rd quarter. Lighthouse Investment Partners LLC now owns 3,200 shares of the company's stock valued at $3,703,000 after buying an additional 343 shares in the last quarter. Raffa Wealth Management LLC bought a new stake in Eli Lilly and Company in the 3rd quarter worth approximately $485,000. Finally, WCG Wealth Advisors LLC lifted its position in Eli Lilly and Company by 8.9% in the 3rd quarter. WCG Wealth Advisors LLC now owns 11,379 shares of the company's stock worth $13,167,000 after buying an additional 927 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
Recent Eli Lilly and Company Headlines
Investors following LLY have been watching these headlines:
- Positive Sentiment: Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, adding experimental treatments for rare blood cancers—essential thrombocythemia and myelofibrosis—to its pipeline. The deal broadens Lilly’s portfolio beyond obesity and diabetes. Lilly adds to buyout streak with $1.5B purchase of startup Calytrix
- Positive Sentiment: Recent coverage highlighted retatrutide beating Novo Nordisk’s Ozempic in a head-to-head trial, reinforcing investor interest in Lilly’s next-generation obesity-drug pipeline and its potential to sustain growth. Lilly’s next potential blockbuster just beat Ozempic head-to-head
- Neutral Sentiment: Lilly also signed a cancer-research deal with Stipple Bio valued at up to $5.9 billion. The collaboration adds another potential source of pipeline growth, but the headline value is a maximum and the available report provides limited detail on payment timing or milestones. Lilly signs cancer research deal with Stipple Bio
About Eli Lilly and Company
(
Get Free Report)
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company's medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.